🔎 Trials Near Me

ホーム › 多発性骨髄腫

米国で参加者を募集している多発性骨髄腫の臨床試験

米国全土の拠点で、多発性骨髄腫に関する239件の研究が参加者を募集しています。

最も多くの研究がある都市

州別

最近更新された研究

公式研究テキスト（英語）

A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant

被験者募集中第2相
60歳以上 · 全性別 · 2026/10/01更新 · NCT06679829

Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies

被験者募集中第1相
18歳〜120歳 · 全性別 · 2026/10/01更新 · NCT06904066

A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma

被験者募集中第3相
18歳以上 · 全性別 · 2026/10/01更新 · NCT07582432

Understanding the Mechanisms of Clonal and Non-clonal Cytopenia Following CAR-T Therapy for Multiple Myeloma or CD19+ Lymphoproliferative Disorder (LPD)

被験者募集中
18歳以上 · 全性別 · 2026/10/01更新 · NCT06630104

A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma

被験者募集中第2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT07589634

The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas

被験者募集中第2相
18歳以上 · 全性別 · 2026/09/30更新 · NCT07285044

SMS-Based Remote Symptom Monitoring for Patients With Plasma Cell Disorders

被験者募集中観察研究
18歳以上 · 全性別 · 2026/09/30更新 · NCT07850284

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

被験者募集中第3相
18歳以上 · 全性別 · 2026/09/30更新 · NCT05519085

Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse

被験者募集中第2相
18歳以上 · 全性別 · 2026/09/30更新 · NCT06948084

A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)

被験者募集中第1相
18歳以上 · 全性別 · 2026/09/29更新 · NCT07409246

A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

被験者募集中第3相
18歳以上 · 全性別 · 2026/09/29更新 · NCT07391657

Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols

被験者募集中観察研究
18歳〜120歳 · 全性別 · 2026/09/28更新 · NCT02682667

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

被験者募集中第2相
18歳〜72歳 · 全性別 · 2026/09/28更新 · NCT03412877

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

被験者募集中第1相
18歳以上 · 全性別 · 2026/09/28更新 · NCT05652335

Tissue Collection for Studies of Lymph Cancer

被験者募集中観察研究
18歳以上 · 全性別 · 2026/09/28更新 · NCT01676805

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/28更新 · NCT04973605

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT05552222

A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT07258511

A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events

被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06500884

A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel

被験者募集中第2相
18歳〜80歳 · 全性別 · 2026/09/25更新 · NCT07149857

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

被験者募集中第4相
18歳以上 · 全性別 · 2026/09/25更新 · NCT05201781

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT04634552

Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study

被験者募集中第2相
60歳以上 · 全性別 · 2026/09/25更新 · NCT06052826

A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT05623020

A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma

被験者募集中第1相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06768489

ClinicalTrials.govより、2026/10/02時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。